Neoplasms

All Conditions

Mouth and Tooth Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Mouth Neoplasms

Head and Neck Neoplasms

Mouth Diseases

Stomatognathic Diseases

Oral Squamous Cell Carcinoma

Oral Cancer

Lip and Oral Cavity Cancer

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Immune Checkpoint Inhibitors

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Patients who underwent neoadjuvant chemoimmunotherapy before surgery

A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.

PD-1 inhibitor+carboplatin+albumin-bound paclitaxel

Jinsong Li

The goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (NACI) regimens in treating advanced oral squamous cell carcinoma (OSCC) patients. We analyzed clinicopathologic features of advanced OSCC patients who received PD-1 inhibitors in combination with carboplatin and paclitaxel before surgical tumor resection between 2020 and 2022. The Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and pathologic response were used to evaluate the efficacy of the NACI treatment. Adverse events apparently related to NACI treatment were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. Disease-free survival (DFS) and overall survival (OS) were calculated using the Kaplan-Meier survival curves and compared using the log rank test. Additionally, we calculated the area under curve (AUC) to compare the predictive value of PD-L1 expression with baseline serum lipid biomarkers for patient response.

Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer

A Pilot Study of Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

The time(years) from day 1 of study treatment until death from any cause.

DFS(by months) is defined as the time from treatment until the date of the first relapse (local/regional recurrence or distant metastasis) or death (from any cause) whichever comes firsts and regardless of whether the patient withdraws from treatment or receives another anti-cancer therapy prior to disease DFS is defined as the time from treatment until the date of the first relapse (local/regional recurrence or distant metastasis) or death (from any cause) whichever comes firsts and regardless of whether the patient withdraws from treatment or receives another anti-cancer therapy prior to disease relapse.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer	NCT06143761	Oral Cancer	PD-1 inhibitor+...	-	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer	NCT06143761	Oral Cancer	PD-1 inhibitor+...	-	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Spots Global Cancer Trial Database for neoadjuvant chemoimmunotherapy, advanced oral squamous cell carcinoma, therapeutic response, predictive marker, prognosis